THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE

被引:4545
作者
CELLA, DF
TULSKY, DS
GRAY, G
SARAFIAN, B
LINN, E
BONOMI, A
SILBERMAN, M
YELLEN, SB
WINICOUR, P
BRANNON, J
ECKBERG, K
LLOYD, S
PURL, S
BLENDOWSKI, C
GOODMAN, M
BARNICLE, M
STEWART, I
MCHALE, M
BONOMI, P
KAPLAN, E
TAYLOR, S
THOMAS, CR
HARRIS, J
机构
[1] RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612
[2] PSYCHOL CORP,SAN ANTONIO,TX
[3] CANC WELLNESS CTR,SKOKIE,IL
关键词
D O I
10.1200/JCO.1993.11.3.570
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We developed and validated a brief, yet sensitive, 33-item general cancer quality-of-life (QL) measure for evaluating patients receiving cancer treatment, called the Functional Assessment of Cancer Therapy (FACT) scale. Methods and Results: The five-phase validation process involved 854 patients with cancer and 15 oncology specialists. The initial pool of 370 overlapping items for breast, lung, and colorectal cancer was generated by open-ended interview with patients experienced with the symptoms of cancer and oncology professionals. Using preselected criteria, items were reduced to a 38-item general version. Factor and scaling analyses of these 38 items on 545 patients with mixed cancer diagnoses resulted in the 28-item FACT-general (FACT-G, version 2). In addition to a total score, this version produces subscale scores for physical, functional, social, and emotional well-being, as well as satisfaction with the treatment relationship. Coefficients of reliability and validity were uniformly high. The scale's ability to discriminate patients on the basis of stage of disease, performance status rating (PSR), and hospitalization status supports its sensitivity. It has also demonstrated sensitivity to change over time. Finally, the validity of measuring separate areas, or dimensions, of QL was supported by the differential responsiveness of subscales when applied to groups known to differ along the dimensions of physical, functional, social, and emotional well-being. Conclusion: The FACT-G meets or exceeds all requirements for use in oncology clinical trials, including ease of administration, brevity, reliability, validity, and responsiveness to clinical change. Selecting it for a clinical trial adds the capability to assess the relative weight of various aspects of QL from the patient's perspective. © 1993 by American Society of Clinical Oncology.
引用
收藏
页码:570 / 579
页数:10
相关论文
共 48 条
  • [1] AARONSON N, 1987, MONOGRAPH SERIES EUR, V17
  • [2] Aaronson N K, 1988, Recent Results Cancer Res, V111, P231
  • [3] AARONSON N K, 1986, P149
  • [4] Aaronson NK., 1991, EFF CANC QUAL LIFE, P185
  • [5] BAROFSKY I, 1990, QUALITY LIFE ASSESSM, P419
  • [6] BAUM M, 1980, EJC SUPPL, V16, P223
  • [7] BROOK RH, 1979, MED CARE, V17, P1
  • [8] Cattell R. B., 1966, HDB MULTIVARIATE EXP
  • [9] CELLA D F, 1988, Comprehensive Therapy, V14, P69
  • [10] Cella D F, 1990, Oncology (Williston Park), V4, P29